Baxter International Inc. (NYSE:BAX)’s Spinoff Is Hinting CTIC’s Success On Pacritinib’s Front – CTIC, ARIA


Dallas, Texas 04/02/2014 (FINANCIALSTRENDS) – The diversified pharmaceutical business Baxter International Inc. (NYSE:BAX) has gained attention for several of its strategic moves to grow its bio-Pharma segment since late 2013. The company entered a strategic alliance over myeloid leukemia drug Pacritinib’s with Cell Therapeutics Inc (NASDAQ:CTIC) last year, then it was found eying for a vaccine business buyer and now it is spinning off the bio-pharma business as a whole. The last of the three moves is a good hint that Pictranib is nearing an approval for commercial production as the approval will be followed up with liquidity infusion from Cell Therapeutics inc (NASDAQ:CTIC) under the marketing collaboration agreement between the two companies.

Pactrinib’s Value Offering to Baxter

As sole -distribution and marketing agent for CTIC’s tri-Kinase inhibitor, Baxter is entitled to payments up to $112 million for regulatory and clinical milestone achievements. Upon commercial launch royalties from on-net sales outside the US, will also accrue to the company. CTIC’s Pacritinib treats malignant Myelofibrosis, (Myeloid leukemia).

Baxter Share Price may Stumble, as BioPharma is Spun-Off

According to accounting and finance experts tax-free spin offs have their way of improving stock prices for two reasons. Firstly, companies only spin off a segment when its nearing a growth phase in its life cycle within a growth industry. According to a report from the center of economic performance (CEP) in Europe, most such tax-free spin-offs perform upbeat while parent companies struggle on the stock screener for a few years to come. Secondly, is a unit is cannibalizing the liquidity arising from elsewhere on the business portfolio. For Baxter International Inc. (NYSE:BAX)’s reason is obvious.

 Amid an assortment of diversified large cap competitors, business of oncology bio-pharma may be a riskier proposition but it offers growth potential for the supply side partners. The CTIC partnership will give it a cash inflow for clinical milestones achieved as well as for

To make things better!

Pacritinib’s, being an, single dose oral treatment has only a few competing drugs. Iclugis from Ariad Pharmaceuticals Inc (NASDAQ:ARIA) a big contender for top spot in Oncology innovation has already been repositioned as a drug of last resorts for its cardiovascular side effects.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.